Novo Nordisk partners with Anthropic to speed drug discovery

Novo Nordisk ↗ 0.02% and Anthropic announced a collaboration on Wednesday to use artificial intelligence in drug discovery and development, as the Danish pharmaceutical giant seeks to speed up its pipeline and regain competitive footing in the GLP-1 market.

Under the partnership, Novo Nordisk's scientists and computational teams will identify core drug discovery challenges, and the two companies will jointly develop targeted solutions for specific scientific workflows to support biological reasoning. As an initial step, Novo Nordisk will test Anthropic's Claude Science model across selected R&D workflows, prioritizing areas where their combined capabilities are expected to deliver the strongest results.nai500+1

"This partnership is another testament to our ambition to become the world's most AI-driven healthcare company," said Mike Doustdar, president and CEO of Novo Nordisk. "AI can help us increase productivity in R&D and compress the path from research to marketed product".manilatimes

Dario Amodei, co-founder and CEO of Anthropic, said the collaboration aims to "compress a century's worth of biological and medical breakthroughs into a decade" by giving researchers access to frontier AI models.manilatimes

A Competitive Landscape

The announcement comes as Novo Nordisk navigates a challenging period. The company's market value has fallen roughly 23% over the past 12 months, and its shares are down more than 16% year-to-date. Once the clear front-runner in the GLP-1 space with blockbuster products Ozempic and Wegovy, Novo Nordisk has steadily lost ground to rival Eli Lilly ↘ 0.79%, which announced a joint AI drug-discovery lab with Nvidia ↗ 2.78% in January, committing up to $1 billion over five years.stocktwits+1

Beyond drug discovery, Novo Nordisk will also use Anthropic's frontier models to strengthen AI-driven software development across the organization, with robust data governance and human oversight mechanisms in place.manilatimes

Pipeline in Focus

Novo Nordisk's pipeline includes CagriSema, a combination therapy being studied in late-stage trials for obesity and diabetes, and an oral weight loss medication that received regulatory approval late last year and is still in the early phase of its commercial rollout. The company also said on Wednesday it will present 44 abstracts at the European Association for the Study of Diabetes symposium later this month.stocktwits+1

The pharmaceutical industry's embrace of AI continues to accelerate. Moderna ↗ 5.27% has partnered with OpenAI and deployed AI tools across its operations, from research to clinical and business functions. Whether Novo Nordisk's deepened AI push will emerge as a catalyst to reset its R&D efficiency and recapture growth momentum remains an open question for investors watching the company's turnaround efforts under new leadership.nai500+1